Multiple Ascending Dose and DDI Study

• Drug: Placebo
  
  Tablets administered once or twice daily, with food, in Part A.
• Drug: PF-06835919
  
  Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
• Drug: atorvastatin
  
  In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.

• Placebo Comparator: Placebo
  
  Tablets administered once or twice daily, with food, in Part A for 14 days.
  Intervention: Drug: Placebo
• Experimental: PF-06835919
  
  Tablets administered once or twice daily, with food, in Part A for 14 days. Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.
  Interventions:
  

  • Drug: PF-06835919
  • Drug: atorvastatin
• Experimental: atorvastatin
  
  In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.
  Interventions:
  

  • Drug: PF-06835919
  • Drug: atorvastatin

Inclusion Criteria:

• Healthy male and females (nonchildbearing potential)
• 18 to 55 years old
• Body Mass Index 17.5 to 30.5

Exclusion Criteria:

• Known hereditary fructose intolerance or fructose malabsorption disorder (Part A)
• Statin intolerance (Part B)
• Unable to consume high fructose syrup-containing beverage with each meal while in the unit (Part A)